Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | Upadacitinib (RINVOQ) - (UP-AA) | Alopecia Areata | NDA Filing | Data Released | Oral | Immunology |
| AbbVie Inc. | RINVOQ (Upadacitinib) - (U-ACHIEVE) | Ulcerative colitis | NDA Filing | Trial Completed | Oral | Gastroenterology |
| AbbVie Inc. | EPKINLY (epcoritamab-bysp) in combination with lenalidomide versus chemo-immunotherapy - (DLBCL-4) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Ongoing | Subcutaneous | Oncology |
| AbbVie Inc. | EPKINLY (epcoritamab-bysp) in combination with standard-of-care rituximab (R-CHOP) - (DLBCL-2) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Ongoing | Subcutaneous | Oncology |
| AbbVie Inc. | Depatuxizumab mafodotin (ABT-414) | Glioblastoma (rGBM) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AbbVie Inc. | Cenicriviroc (CVC) | Nonalcoholic steatohepatitis (NASH) | Phase 3 | Trial Discontinued | Oral | Gastroenterology |
| AbbVie Inc. | VENCLEXTA (venetoclax) - (CANOVA) | Relapsed or refractory multiple myeloma | Phase 3 | Data Released | Oral | Oncology |
| AbbVie Inc. | Mirvetuximab soravtansine - (FORWARD II) | Ovarian cancer and relapsed endometrial cancer | Phase 3 | Ongoing | Intravenous | Oncology |
